US 11559588
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
granted A61KA61K38/465A61K48/005
Quick answer
US patent 11559588 (Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders) held by CRISPR THERAPEUTICS AG expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K38/465, A61K48/005